Below are the most recent publications written about "Risperidone" by people in Profiles.
-
Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatr Serv. 2016 12 01; 67(12):1370-1372.
-
Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar; 41(2):449-59.
-
Song X, Li X, Gao J, Zhao J, Li Y, Fan X, Lv L. APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia. PLoS One. 2014; 9(4):e93902.
-
Song X, Fan X, Li X, Zhang W, Gao J, Zhao J, Harrington A, Ziedonis D, Lv L. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na?ve, first-episode schizophrenia. Psychopharmacology (Berl). 2014 Jan; 231(2):319-25.
-
Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013 Jan-Feb; 21(1):18-40.
-
Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry. 2012 May; 51(5):496-505.
-
Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010 Jun; 49(6):583-94; quiz 632.
-
Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008 Nov; 165(11):1420-31.
-
Ghaznavi S, Nakic M, Rao P, Hu J, Brewer JA, Hannestad J, Bhagwagar Z. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry. 2008 Jul; 165(7):813-8.
-
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008 Mar; 100(1-3):39-52.